Substantial preclinical evidence had demonstrated that pharmacological activation of the STING signaling axis could significantly enhance tumor immunogenicity, potentiate cytotoxic T lymphocyte infiltration, and suppress both primary tumor progression and metastatic dissemination [[21], [22], [23]]. The gene discussed is STING1; the disease is neoplasm.